{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T23:00:16Z","timestamp":1726268416023},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T00:00:00Z","timestamp":1362700800000},"content-version":"vor","delay-in-days":8377,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:p>Data from 58 premarketing studies of the nonsteroidal antiinflammatory drug flurbiprofen were pooled for analyses of adverse drug reactions (ADRs). These studies included 5602 patients treated with flurbiprofen (N = 4123), aspirin (N = 1033), or placebo (N = 446) for varying durations. Diagnoses included rheumatoid arthritis, osteoarthritis, and other painful musculoskeletal conditions. In these studies serious upper gastrointestinal ADRs occurred in flurbiprofen\u2010treated patients at less than one half the rate seen in aspirin\u2010treated patients. The incidence of serious urinary tract ADRs was lower with flurbiprofen than with aspirin. The flurbiprofen group had no serious clinical ADRs related to the hemic\/lymphatic system. The most common laboratory abnormality was a decrease in hematocrit, which occurred less often than in the aspirin group. We also evaluated serious flurbiprofen\u2010related ADRs in 4370 patients in a variety of other studies and reviewed published reports of flurbiprofen clinical trials and case reports. These reviews showed no additional, unanticipated patterns of intolerance. These clinical safety data indicate that in the doses studied, flurbiprofen is a well tolerated agent for patients requiring nonsteroidal antiinflammatory drug therapy.<\/jats:p>","DOI":"10.1002\/j.1552-4604.1990.tb03604.x","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T21:34:22Z","timestamp":1362778462000},"page":"342-351","source":"Crossref","is-referenced-by-count":11,"title":["Clinical Safety of Flurbiprofen"],"prefix":"10.1002","volume":"30","author":[{"given":"Carter D.","family":"Brooks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto I.","family":"Linet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Schellenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lana F.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Defesche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kok\u2010Wah","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian H.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Assenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90104-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2510080308"},{"key":"e_1_2_1_4_2","volume-title":"Coding Symbols for Thesaurus of Adverse Reaction Terms. Second Edition.","author":"U.S. Food and Drug Administration","year":"1985"},{"key":"e_1_2_1_5_2","first-page":"87","article-title":"Pr\u00e9vention secondaire des infarctus c\u00e9r\u00e9braux dus \u00e0 l'ath\u00e8roscl\u00e8rose. Comparaison \u00e0 trois ans du flurbiprof\u00e8ne et d'un d\u00e8rive de l'ergot de seigle","volume":"13","author":"Dehen H","year":"1984","journal-title":"Presse Med"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine1962.26.230"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90714-2"},{"key":"e_1_2_1_8_2","first-page":"130","article-title":"Prospective di therapia con antagonisti e inhibitors di leukotrieni e prostaglandine","volume":"53","author":"Bono L","year":"1983","journal-title":"Lotta Tuberc Mal Polm Soc"},{"key":"e_1_2_1_9_2","first-page":"803","article-title":"Near\u2010fatal bronchospasm in an asthmatic patient following ingestion of flurbiprofen: A case report","volume":"61","author":"Cohen RD","year":"1982","journal-title":"S Afr Med J"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1987.01660330077013"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03259825"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300518"},{"key":"e_1_2_1_13_2","first-page":"679","article-title":"Review of yellow cards (1986): Report to the Committee on the Safety of Medicines","volume":"36","author":"Bern JL","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000199027"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92393-2"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1987.00370010087021"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.46.8.640"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92892-9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90085-9"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198428040-00002"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt19689194"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198835030-00004"},{"key":"e_1_2_1_23_2","first-page":"562","article-title":"Rare adverse reactions to nonsteroidal anti\u2010inflammatory drugs (Part 3)","volume":"12","author":"O'Brien WM","year":"1985","journal-title":"J Rheumatol"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6529.1190"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03172.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1987.164"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(88)90042-X"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90084-7"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198600324-00009"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(86)80108-1"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1988.tb03176.x"},{"key":"e_1_2_1_32_2","first-page":"348","article-title":"Naproxen tolerability in the elderly: A summary report","volume":"14","author":"Geczy M","year":"1987","journal-title":"J Rheumatol"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(84)80015-7"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1982.tb03171.x"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(88)90040-6"},{"key":"e_1_2_1_36_2","first-page":"1283","article-title":"Drug\u2010induced allergic and hypersensitivity reactions","volume":"227","author":"Griffin JP","year":"1983","journal-title":"The Practitioner"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780301009"},{"key":"e_1_2_1_38_2","first-page":"695","article-title":"The effect of indication on the risk of hypersensitivity reactions associated with tolmetin sodium vs other nonsteroidal anti\u2010inflammatory drugs","volume":"15","author":"Strom BL","year":"1988","journal-title":"J Rheumatol"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.1988.tb02838.x"},{"key":"e_1_2_1_40_2","first-page":"785","article-title":"Rare adverse reactions to nonsteroidal anti\u2010inflammatory drugs (Part 4)","volume":"12","author":"O'Brien WM","year":"1985","journal-title":"J Rheumatol"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fj.1552-4604.1990.tb03604.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/j.1552-4604.1990.tb03604.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T20:06:28Z","timestamp":1698005188000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/j.1552-4604.1990.tb03604.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1002\/j.1552-4604.1990.tb03604.x"],"URL":"https:\/\/doi.org\/10.1002\/j.1552-4604.1990.tb03604.x","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}